3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness

Sorafenib is the FDA-approved first-line target drug for HCC patients. However, sorafenib only confers 3–5 months of survival benefit with <30% of HCC patients. Thus, it is necessary to develop a sensitizer for hepatocellular carcinoma (HCC) to sorafenib. Here, we report that in representative HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Guifang, Shi, Zhaopeng, Liu, Dan, Zhang, Shaoyi, Zhu, Hui, Wang, Yugang, Mi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260721/
https://www.ncbi.nlm.nih.gov/pubmed/34230478
http://dx.doi.org/10.1038/s41420-021-00561-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260721/
https://www.ncbi.nlm.nih.gov/pubmed/34230478
http://dx.doi.org/10.1038/s41420-021-00561-6

Ejemplares similares